Federico Longo1, Mónica Jorge2, Ricardo Yaya3, Ana Fernández Montes4, Nieves Martínez Lago5, Elena Brozos6, Jorge Aparicio7, Guillermo Quintero8, Eduardo Ceballos9, Elvira Buxó10, Ana Maria Lopez11, Maria Luz Pellón12, Raquel Molina13, Laura Diaz-Paniagua14, Paula Cerdà15, Pedro Lopez Leiva16, Alfonso Martín Carnicero17, Antía Cousillas18, Lorena Paris19, Beatriz García-Paredes20, Carlos Romero21, María Ortega22, Alberto Molero22, Sergio de la Torre22, Min-Hua Jen23, Silvia Díaz-Cerezo22. 1. Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, 28034, Spain. 2. Hospital Álvaro Cunqueiro, Vigo (Pontevedra), 36213, Spain. 3. Instituto Valenciano de Oncología (IVO), Valencia, 46009, Spain. 4. Complexo Universitario Hospitalario de Ourense, 32005, Spain. 5. Complejo Hospitalario Universitario, A Coruña, 15006, Spain. 6. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela (La Coruña), 15706, Spain. 7. Hospital Universitario y Politécnico La Fe, Valencia, 46026, Spain. 8. Hospital Universitario Lucus Augusti, Lugo, 27003, Spain. 9. Hospital San Pedro de Alcántara, Cáceres, 10003, Spain. 10. Hospital Quirón Salud, Barcelona, 08023, Spain. 11. Hospital Universitario de Burgos, 09006, Spain. 12. Complexo Universitario Hospitalario de El Ferrol (La Coruña), 15405, Spain. 13. Hospital Universitario Príncipe de Asturias, Alcalá de Henares (Madrid), 28805, Spain. 14. Hospital Universitario de Getafe (Madrid), 28905, Spain. 15. Centro Médico Teknon, Barcelona, 08022, Spain. 16. Complejo Hospitalario de Jaén, 23007, Spain. 17. Hospital de San Pedro, Logroño, 26006, Spain. 18. Complexo Universitario Hospitalario de Pontevedra, 36071, Spain. 19. Centro Oncológico de Galicia, La Coruña, 15009, Spain. 20. Hospital Clínico San Carlos, Madrid, 28040, Spain. 21. Hospital POVISA, Vigo (Pontevedra), 36201, Spain. 22. Department of Medical, Lilly, Madrid, 28108, Spain. 23. European Statistics Group, Lilly, Surrey, GU206PH, UK.
Abstract
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4-4.3) and 7.4 (95% CI: 6.4-8.9) in combination regimen and 2.0 (1.1-2.8) and 4.3 (95% CI: 1.9-7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials.
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4-4.3) and 7.4 (95% CI: 6.4-8.9) in combination regimen and 2.0 (1.1-2.8) and 4.3 (95% CI: 1.9-7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials.
Authors: Sena Valcarcel; Javier Gallego; Paula Jimenez-Fonseca; Marc Diez; Eva Martínez de Castro; Raquel Hernandez; Virginia Arrazubi; Ana Custodio; Juana María Cano; Ana Fernández Montes; Ismael Macias; Laura Visa; Aitana Calvo; Rosario Vidal Tocino; Nieves Martínez Lago; María Luisa Limón; Mónica Granja; Mireia Gil; Paola Pimentel; Lola Macia-Rivas; Carolina Hernández Pérez; Montserrat Mangas; Alfonso Martín Carnicero; Paula Cerdà; Lucía Gomez Gonzalez; Francisco Garcia Navalon; Mª Dolores Mediano Rambla; Marta Martin Richard; Alberto Carmona-Bayonas Journal: J Cancer Res Clin Oncol Date: 2022-08-30 Impact factor: 4.322
Authors: Victor Mihai Sacerdoțianu; Bogdan Silviu Ungureanu; Sevastiţa Iordache; Sergiu Marian Cazacu; Daniel Pirici; Ilona Mihaela Liliac; Daniela Elena Burtea; Valeriu Șurlin; Cezar Stroescu; Dan Ionuț Gheonea; Adrian Săftoiu Journal: J Pers Med Date: 2022-06-21